Vertex, insurers battle over CF drugs; spinal cord device restores hand movement for two stroke survivors

A growing number of cystic fibrosis patients are struggling with drug costs due to a battle between drugmakers and insurers.

February 20, 2023 Check out STAT+

Sponsored By

Our apologies for the incorrect newsletter sent this afternoon. Below is today's roundup.

Kim Raff for STAT 'Caught in the middle': A battle between Vertex and insurers is leaving cystic fibrosis patients with crushing drug costs A growing number of cystic fibrosis patients are struggling with drug costs due to a battle between drugmakers and insurers. By Ed Silverman A device restored hand movement for two stroke survivors. Researchers want to take it mainstream A small, early-stage study suggests stimulating the top part of the spine can improve arm and hand movement in post-stroke patients. By Lizzy Lawrence Opinion: Medicaid during incarceration: a step toward health equity Activating Medicaid 90 days before incarceration ends can help people get much-needed health care when they return to their communities. By Shira Shavit AP Photo/Felipe Dana Opinion: In Turkey, Ukraine, and beyond, the necessity of trauma care More doctors need to be trained to deal with the immediate and aftereffects of trauma — their patients and their own. By MarkAlain Déry STAT+ | First non-immunosuppressive drug approved for a rare and deadly kidney disease after news of the approval — and that the drug's label would include a hefty set of "black box" warnings — shares of Travere dropped. By Jonathan Wosen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

REPORTS NEWSLETTERS EVENTS STAT+

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser